Ivermectin Usage Accelerates While the Need for Data is Real: How About an Ivermectin Registry?

Ivermectin Usage Accelerates While the Need for Data is Real How about an Ivermectin Registry

TrialSite News’ interview with Tarek Alam, head of medicine department at Bangladesh Medical College, has led to considerable interest in regional hospital protocol-approved, off-label use of ivermectin and the antibiotic Doxycycline in patients diagnosed with mild cases of COVID-19. Thus far, Dr. Alam reaffirmed to TrialSite News their “outstanding results.” A number of developing economy-based nations are embracing ivermectin as a low-cost approach to fighting at least mild cases of COVID-19—despite the lack of data from randomized controlled trials. Most recently, TrialSite News learned that the government in Peru has accepted Ivermectin as a COVID-19 treatment, and we helped share with the world the fact that Bolivia is handing out up to 350,000 doses of the antiparasitic drug to those with mild COVID-19 symptoms. Hundreds of thousands of readers have visited TrialSite News’ ivermectin articles with hundreds of messages and a number of requests from other nations to make introductions for planned ivermectin research.

The Bangladesh Medical College Interview

Our interview with Dr. Alam was enlightening. By leveraging the TrialSite Investigators Network (a large database o...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee